Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Article image or reusable cover for TechCrunch AI
The round valued the AI biotech at $2 billion.
It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Read the full story at TechCrunch AI →
The text is the source's own description of its publication. The content belongs to TechCrunch AI.
More from TechCrunch AI
Apple CEO says the company doesn’t ‘want to ship AI for AI’s sake’
TechCrunch AI 11 h ago
4 days left: How TechCrunch Founder Summit helps you make more useful connections to scale
TechCrunch AI 11 h ago
Judge allows NAACP lawsuit over xAI data center pollution to move forward
TechCrunch AI 11 h ago
OpenAI reportedly lowers funding target for new round
TechCrunch AI 16 h ago